104 Recruiting Renal Cell Carcinoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Renal Cell Carcinoma
Related Conditions
Top Recruiting Renal Cell Carcinoma Studies
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
📍 UT Southwestern Medical Center — Dallas, Texas
View Study & Checklist ➔Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
📍 Stanford School of Medicine — Stanford, California
View Study & Checklist ➔Follow-up After Metastasectomy in Patients With Kidney Cancer
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
📍 Exelixis Clinical Site #116 — La Jolla, California
View Study & Checklist ➔A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
📍 Johns Hopkins — Baltimore, Maryland
View Study & Checklist ➔Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
📍 Duke Cancer Institute — Durham, North Carolina
View Study & Checklist ➔Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
📍 Baylor College of Medicine — Houston, Texas
View Study & Checklist ➔A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
📍 Arizona Oncology Associates, PC HOPE (A)A HOPE) — Tucson, Arizona
View Study & Checklist ➔Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation
📍 London Regional Cancer Program of the Lawson Health Research Institute — London, Ontario
View Study & Checklist ➔Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
📍 Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
View Study & Checklist ➔Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
📍 Portland Providence Medical Center — Portland, Oregon
View Study & Checklist ➔Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC
📍 University of Texas Southwestern Medical Center — Dallas, Texas
View Study & Checklist ➔A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
📍 Local Institution - 0013 — Washington D.C., District of Columbia
View Study & Checklist ➔A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
📍 City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104) — Duarte, California
View Study & Checklist ➔Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
📍 Georgetown University Medical Center ( Site 1002) — Washington D.C., District of Columbia
View Study & Checklist ➔177LuPSMA in Renal Cell Carcinoma
📍 Brigham and Women's Hospital — Boston, Massachusetts
View Study & Checklist ➔Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology
📍 Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
View Study & Checklist ➔High Dose IL 2 and Entinostat in RCC
📍 Univeristy of Southern California — Los Angeles, California
View Study & Checklist ➔Delving Into Participation Trends in Renal Cell Carcinoma Studies
📍 Power Life Sciences — San Francisco, California
View Study & Checklist ➔Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
📍 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio
View Study & Checklist ➔Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)
📍 Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania
View Study & Checklist ➔Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Drug Screening Using Novel IMD in Renal Cell Carcinoma
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
📍 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
View Study & Checklist ➔Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites) — Basking Ridge, New Jersey
View Study & Checklist ➔Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
📍 Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania
View Study & Checklist ➔Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
📍 Sunnybrook Health Sciences — Toronto, Ontario
View Study & Checklist ➔Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
📍 UCSF Medical Center at Mission Bay ( Site 5008) — San Francisco, California
View Study & Checklist ➔Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
📍 City of Hope — Irvine, California
View Study & Checklist ➔A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
📍 Alaska Oncology and Hematology ( Site 0133) — Anchorage, Alaska
View Study & Checklist ➔A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
📍 University of Arizona Cancer Center — Tucson, Arizona
View Study & Checklist ➔Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
📍 University of Texas Southwestern Medical Center — Dallas, Texas
View Study & Checklist ➔